Establishment of bladder cancer spheroids and cultured in microfluidic platform for predicting drug response.
Qiao XiongTing LiuYidie YingXiaowen YuZiwei WangHongliang GaoTianhai LinWeihua FanZhensheng ZhangQiang WeiYuqing GeShuxiong ZengChuanliang XuPublished in: Bioengineering & translational medicine (2023)
Cisplatin-containing combination chemotherapy has been used as the standard treatment for bladder cancer patients at advanced stage. However, nearly 50% of patients are nonresponders. To guide the selection of more effective chemotherapeutic agents, a bladder cancer spheroids microfluidic drug sensitivity analysis system was established in this study. Bladder cancer spheroids were established and successfully cultured in a customized microfluidic device to assess their response to different chemotherapeutic agents. The in vitro drug sensitivity results were also compared to patient-derived xenograft (PDX) models and clinical responses of patients. As a result, bladder cancer spheroids faithfully recapitulate the histopathological and genetic features of their corresponding parental tumors. Furthermore, the in vitro drug sensitivity outcomes of spheroids ( n = 8) demonstrated a high level of correlation with the PDX ( n = 2) and clinical response in patients ( n = 2). Our study highlights the potential of combining bladder cancer spheroids and microfluidic devices as an efficient and accurate platform for personalized selection of chemotherapeutic agents.
Keyphrases
- end stage renal disease
- ejection fraction
- high throughput
- chronic kidney disease
- newly diagnosed
- single cell
- peritoneal dialysis
- circulating tumor cells
- metabolic syndrome
- endothelial cells
- emergency department
- gene expression
- adipose tissue
- climate change
- insulin resistance
- adverse drug
- radiation therapy
- genome wide
- rectal cancer
- copy number
- muscle invasive bladder cancer